Overview

A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects

Status:
Completed

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

A single dose escalation study to determine the safety, tolerability, and pharmacokinetic profile of intramuscular and subcutaneous injections of GSK1265744 long acting parenteral (LAP) in healthy subjects. This study consists of a screening visit, a single injection, and follow-up evaluations for a minimum of 12 weeks following the injection.

Phase:

Phase 1

Details

Lead Sponsor:

ViiV Healthcare

Collaborator:

GlaxoSmithKline

Treatments:

Cabotegravir